Review Article

Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy

Table 9

PI Dosing Recommendations for G1 Patients [5, 6].

MedicationDosing

Boceprevir (BOC)* 
Treatment-naïve without cirrhosis
PEG-IFN/RBV for 4 weeks, then BOC 800 mg (four 200 mg capsules) orally 3 times daily (every 7–9 hours) with food [meal/light snack] to PEG-IFN/RBV regimen after 4 weeks of treatment—then RGT

Boceprevir* 
Treatment-naïve patients with cirrhosis
4 weeks PEG-IFN/RBV followed by 44 weeks BOC 800 mg (four 200 mg capsules) 3 times daily (every 7–9 hours) in combination with PEG-IFN/RBV

Telaprevir (TVR)**TVR 750 mg (two 375 mg tablets) taken orally 3 times a day (7–9 hours apart) with food in combination with PEG-IFN/RBV for 12 weeks

*No dosage adjustment required for patients with any degree of renal impairment or for mild, moderate, or severe hepatic impairment.
**Not recommended for patients with moderate or severe hepatic impairment (Child-Pugh B or C, score ≥ to 7) or patients with decompensated liver disease.
RGT: response-guided therapy.